Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
Latest Information Update: 10 Jan 2024
At a glance
- Drugs Tasurgratinib (Primary)
- Indications Cholangiocarcinoma; CNS cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms FORTUNE
- 04 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2022 Trial design, published in the BMC Cancer
- 20 Jul 2021 New trial record